{"id":"non-arotinolol-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL93298","moleculeType":"Small molecule","molecularWeight":"371.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Beta-blockers work by antagonizing beta-adrenergic receptors, reducing heart rate and blood pressure. This class excludes arotinolol specifically, encompassing other beta-blocking agents used in hypertension and cardiac conditions. The exact mechanism depends on the specific beta-blocker within this non-arotinolol classification.","oneSentence":"Non-arotinolol group refers to beta-blockers that are structurally distinct from arotinolol, used primarily for cardiovascular conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:57:27.457Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"},{"name":"Cardiac arrhythmias"}]},"trialDetails":[{"nctId":"NCT06780865","phase":"NA","title":"Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute of Hypertension","startDate":"2025-01-30","conditions":"Chronic Kidney Disease(CKD), Nocturnal Hypertension","enrollment":200},{"nctId":"NCT01351636","phase":"PHASE4","title":"Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2011-04","conditions":"Chronic Kidney Disease","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Control group"],"phase":"marketed","status":"active","brandName":"Non arotinolol group","genericName":"Non arotinolol group","companyName":"Sumitomo Pharma (Suzhou) Co., Ltd.","companyId":"sumitomo-pharma-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Non-arotinolol group refers to beta-blockers that are structurally distinct from arotinolol, used primarily for cardiovascular conditions. Used for Hypertension, Angina pectoris, Cardiac arrhythmias.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}